| Literature DB >> 30154376 |
Trang Thi Huyen Nguyen1, Ramesh Prasad Pandey2,3, Prakash Parajuli4, Jang Mi Han5, Hye Jin Jung6,7, Yong Il Park8, Jae Kyung Sohng9,10.
Abstract
Anthraquinones, naturally occurring bioactive compounds, have been reported to exhibit various biological activities, including anti-inflammatory, antiviral, antimicrobial, and anticancer effects. In this study, we biotransformed three selected anthraquinones into their novel O-glucoside derivatives, expressing a versatile glycosyltransferase (YjiC) from Bacillus licheniformis DSM 13 in Escherichia coli. Anthraflavic acid, alizarin, and 2-amino-3-hydroxyanthraquinone were exogenously fed to recombinant E. coli as substrate for biotransformation. The products anthraflavic acid-O-glucoside, alizarin 2-O-β-d-glucoside, and 2-amino-3-O-glucosyl anthraquinone produced in the culture broths were characterized by various chromatographic and spectroscopic analyses. The comparative anti-proliferative assay against various cancer cells (gastric cancer-AGS, uterine cervical cancer-HeLa, and liver cancer-HepG2) were remarkable, since the synthesized glucoside compounds showed more than 60% of cell growth inhibition at concentrations ranging from ~50 μM to 100 μM. Importantly, one of the synthesized glucoside derivatives, alizarin 2-O-glucoside inhibited more than 90% of cell growth in all the cancer cell lines tested.Entities:
Keywords: anthraquinones; anti-cancer agents; glycosyltransferase
Mesh:
Substances:
Year: 2018 PMID: 30154376 PMCID: PMC6225150 DOI: 10.3390/molecules23092171
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Scheme showing pathway and utilizing Escherichia coli indigenous UDP-glucose by Bacillus glycosyltransferase for modification of selected anthraquinones into respective glucosides.
Figure 2HPLC-PDA chromatogram of biotransformation reaction mixtures compared with respective standards. S refers to the substrate peak and P refers to the product. (A) 2-amino-3-hydroxyanthraquinone, (B) alizarin, and (C) anthraflavic acid.
Figure 3HQ-QTOF ESI/MS analyses of glycosylated (A) 2-amino-3-hydroxyanthraquinone; (B) Alizarin; and (C) anthraflavic acid confirmed by comparing the mass fragments.
Figure 4Production profile of anthraquinone-O-glucoside at different incubation time intervals and glucose supplementations. (A) Alizarin, (B) anthraflavic acid, and (C) 2-amino-3-hydroxyanthraquinone.
Figure 5Inhibitory effects of anthraquinones and their derivatives on cancer cell AGS (gastric cancer cell), HeLa (cervical cancer cell), and HepG2 (Liver cancer cell) growth. (1) Anthraflavic acid; (2) Alizarin; (3) 2-amino-3-hydroxyanthraquinone; (4) Anthraflavic acid-O-glucoside; (5) Alizarin-O-glucoside; (6) 2-amino-3-O-glucoxyanthraquinone.
Figure 6Percentage conversion of alizarin-2-O-β-d-glucoside in bioreactor at different incubation time intervals.
Figure 71H- and 13C-NMR of alizarin and alizarin-2-O-β-d-glucoside.
Comparison of 1H- and 13C-NMR spectra of alizarin and alizarin 2-O-glucoside measured in DMSO-d. Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet), including coupling constant J.
| Position | 1H-NMR | 13C-NMR | ||
|---|---|---|---|---|
| Alizarin | Alizarin 2- | Alizarin | Alizarin 2- | |
| 1-OH | 12.59 ( | 12.62 ( | 153.15 | 155.25 |
| 2-OH | 10.88 ( | - | 151.17 | 151.56 |
| 3 | 7.20 ( | 7.53 ( | 121.55 | 120.78 |
| 4 | 7.62 ( | 7.64 ( | 121.23 | 120.55 |
| 5 | 8.15 ( | 8.14 ( | 126.88 | 126.97 |
| 6 | 7.89 ( | 7.89 ( | 133.44 | 134.76 |
| 7 | 7.89 ( | 7.89 ( | 135.51 | 135.65 |
| 8 | 8.15 ( | 8.14 ( | 127.12 | 127.20 |
| 9 | - | - | 180.93 | 181.21 |
| 10 | - | - | 189.16 | 188.85 |
| 11 | - | - | 133.22 | 133.26 |
| 12 | - | - | 133.94 | 133.69 |
| 13 | - | - | 116.64 | 116.60 |
| 14 | - | - | 124.17 | 126.14 |
| 1′ | - | 5.17 ( | - | 100.00 |
| 2′ | - | 3.36 ( | - | 73.51 |
| 3′ | - | 3.36 ( | - | 77.17 |
| 4′ | - | 3.49 ( | - | 77.66 |
| 5′ | - | 3.25 ( | - | 69.94 |
| 6′a | - | 3.72 ( | - | 61.01 |
| 6′b | 3.49 (m, 1H) | |||